vs
Side-by-side financial comparison of Acadian Asset Management Inc. (AAMI) and Esperion Therapeutics, Inc. (ESPR). Click either name above to swap in a different company.
Acadian Asset Management Inc. is the larger business by last-quarter revenue ($172.2M vs $168.4M, roughly 1.0× Esperion Therapeutics, Inc.). On growth, Esperion Therapeutics, Inc. posted the faster year-over-year revenue change (143.7% vs 2.6%). Over the past eight quarters, Acadian Asset Management Inc.'s revenue compounded faster (27.6% CAGR vs 10.6%).
United Asset Management was an American holding company headquartered in Boston, Massachusetts.
Esperion Therapeutics, Inc. is a publicly traded American pharmaceutical company focused on the development of bempedoic acid, an orally available small molecule designed to lower elevated levels of LDL-C. The company is headquartered in Ann Arbor, Michigan.
AAMI vs ESPR — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $172.2M | $168.4M |
| Net Profit | $34.7M | — |
| Gross Margin | — | — |
| Operating Margin | 33.3% | 50.6% |
| Net Margin | 20.2% | — |
| Revenue YoY | 2.6% | 143.7% |
| Net Profit YoY | -18.4% | — |
| EPS (diluted) | $0.97 | $0.32 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $172.2M | $168.4M | ||
| Q3 25 | $144.2M | $87.3M | ||
| Q2 25 | $127.4M | $82.4M | ||
| Q1 25 | $119.9M | $65.0M | ||
| Q4 24 | $167.8M | $69.1M | ||
| Q3 24 | $123.1M | $51.6M | ||
| Q2 24 | $109.0M | $73.8M | ||
| Q1 24 | $105.7M | $137.7M |
| Q4 25 | $34.7M | — | ||
| Q3 25 | $15.1M | $-31.3M | ||
| Q2 25 | $10.1M | $-12.7M | ||
| Q1 25 | $20.1M | $-40.5M | ||
| Q4 24 | $42.5M | — | ||
| Q3 24 | $16.9M | $-29.5M | ||
| Q2 24 | $11.0M | $-61.9M | ||
| Q1 24 | $14.6M | $61.0M |
| Q4 25 | 33.3% | 50.6% | ||
| Q3 25 | 18.4% | -11.4% | ||
| Q2 25 | 12.7% | 8.6% | ||
| Q1 25 | 26.6% | -34.0% | ||
| Q4 24 | 38.7% | -6.4% | ||
| Q3 24 | 21.9% | -31.0% | ||
| Q2 24 | 18.9% | 3.5% | ||
| Q1 24 | 21.7% | 52.5% |
| Q4 25 | 20.2% | — | ||
| Q3 25 | 10.5% | -35.9% | ||
| Q2 25 | 7.9% | -15.4% | ||
| Q1 25 | 16.8% | -62.2% | ||
| Q4 24 | 25.3% | — | ||
| Q3 24 | 13.7% | -57.2% | ||
| Q2 24 | 10.1% | -83.9% | ||
| Q1 24 | 13.8% | 44.3% |
| Q4 25 | $0.97 | $0.32 | ||
| Q3 25 | $0.42 | $-0.16 | ||
| Q2 25 | $0.28 | $-0.06 | ||
| Q1 25 | $0.54 | $-0.21 | ||
| Q4 24 | $1.11 | $-0.14 | ||
| Q3 24 | $0.45 | $-0.15 | ||
| Q2 24 | $0.29 | $-0.33 | ||
| Q1 24 | $0.37 | $0.34 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $167.9M |
| Total DebtLower is stronger | $200.0M | — |
| Stockholders' EquityBook value | — | $-302.0M |
| Total Assets | $677.0M | $465.9M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $167.9M | ||
| Q3 25 | — | $92.4M | ||
| Q2 25 | — | $86.1M | ||
| Q1 25 | — | $114.6M | ||
| Q4 24 | — | $144.8M | ||
| Q3 24 | — | $144.7M | ||
| Q2 24 | — | $189.3M | ||
| Q1 24 | — | $226.6M |
| Q4 25 | $200.0M | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $275.0M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | $-302.0M | ||
| Q3 25 | — | $-451.4M | ||
| Q2 25 | — | $-433.5M | ||
| Q1 25 | — | $-426.2M | ||
| Q4 24 | — | $-388.7M | ||
| Q3 24 | — | $-370.2M | ||
| Q2 24 | — | $-344.2M | ||
| Q1 24 | — | $-294.3M |
| Q4 25 | $677.0M | $465.9M | ||
| Q3 25 | $751.4M | $364.0M | ||
| Q2 25 | $672.3M | $347.1M | ||
| Q1 25 | $677.3M | $324.0M | ||
| Q4 24 | $703.2M | $343.8M | ||
| Q3 24 | $555.2M | $314.1M | ||
| Q2 24 | $533.1M | $352.3M | ||
| Q1 24 | $544.9M | $373.1M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-2.4M | $45.2M |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | 0.0% |
| Cash ConversionOCF / Net Profit | -0.07× | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-2.4M | $45.2M | ||
| Q3 25 | $-23.9M | $-4.3M | ||
| Q2 25 | $61.6M | $-31.4M | ||
| Q1 25 | $-48.8M | $-22.6M | ||
| Q4 24 | $55.8M | $-35.0M | ||
| Q3 24 | $69.6M | $-35.3M | ||
| Q2 24 | $45.7M | $-7.2M | ||
| Q1 24 | $-40.4M | $53.8M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | $-35.5M | ||
| Q2 24 | — | $-7.3M | ||
| Q1 24 | — | $53.8M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | -68.7% | ||
| Q2 24 | — | -9.9% | ||
| Q1 24 | — | 39.0% |
| Q4 25 | — | 0.0% | ||
| Q3 25 | — | 0.0% | ||
| Q2 25 | — | 0.0% | ||
| Q1 25 | — | 0.0% | ||
| Q4 24 | — | 0.0% | ||
| Q3 24 | — | 0.3% | ||
| Q2 24 | — | 0.1% | ||
| Q1 24 | — | 0.1% |
| Q4 25 | -0.07× | — | ||
| Q3 25 | -1.58× | — | ||
| Q2 25 | 6.10× | — | ||
| Q1 25 | -2.43× | — | ||
| Q4 24 | 1.31× | — | ||
| Q3 24 | 4.12× | — | ||
| Q2 24 | 4.15× | — | ||
| Q1 24 | -2.77× | 0.88× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AAMI
Segment breakdown not available.
ESPR
| Collaboration Revenue | $124.7M | 74% |
| Products | $43.7M | 26% |
